These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 29570723)
1. HIV treatment eligibility expansion and timely antiretroviral treatment initiation following enrollment in HIV care: A metaregression analysis of programmatic data from 22 countries. Tymejczyk O; Brazier E; Yiannoutsos C; Wools-Kaloustian K; Althoff K; Crabtree-Ramírez B; Van Nguyen K; Zaniewski E; Dabis F; Sinayobye JD; Anderegg N; Ford N; Wikramanayake R; Nash D; PLoS Med; 2018 Mar; 15(3):e1002534. PubMed ID: 29570723 [TBL] [Abstract][Full Text] [Related]
2. Long-term HIV care outcomes under universal HIV treatment guidelines: A retrospective cohort study in 25 countries. Brazier E; Tymejczyk O; Wools-Kaloustian K; Jiamsakul A; Torres MTL; Lee JS; Abuogi L; Khol V; Mejía Cordero F; Althoff KN; Law MG; Nash D; PLoS Med; 2024 Mar; 21(3):e1004367. PubMed ID: 38498589 [TBL] [Abstract][Full Text] [Related]
3. Changes in rapid HIV treatment initiation after national "treat all" policy adoption in 6 sub-Saharan African countries: Regression discontinuity analysis. Tymejczyk O; Brazier E; Yiannoutsos CT; Vinikoor M; van Lettow M; Nalugoda F; Urassa M; Sinayobye JD; Rebeiro PF; Wools-Kaloustian K; Davies MA; Zaniewski E; Anderegg N; Liu G; Ford N; Nash D; PLoS Med; 2019 Jun; 16(6):e1002822. PubMed ID: 31181056 [TBL] [Abstract][Full Text] [Related]
4. Estimating the real-world effects of expanding antiretroviral treatment eligibility: Evidence from a regression discontinuity analysis in Zambia. Mody A; Sikazwe I; Czaicki NL; Wa Mwanza M; Savory T; Sikombe K; Beres LK; Somwe P; Roy M; Pry JM; Padian N; Bolton-Moore C; Holmes CB; Geng EH PLoS Med; 2018 Jun; 15(6):e1002574. PubMed ID: 29870531 [TBL] [Abstract][Full Text] [Related]
5. Access to antiretroviral therapy in HIV-infected children aged 0-19 years in the International Epidemiology Databases to Evaluate AIDS (IeDEA) Global Cohort Consortium, 2004-2015: A prospective cohort study. Desmonde S; Tanser F; Vreeman R; Takassi E; Edmonds A; Lumbiganon P; Pinto J; Malateste K; McGowan C; Kariminia A; Yotebieng M; Dicko F; Yiannoutsos C; Mubiana-Mbewe M; Wools-Kaloustian K; Davies MA; Leroy V; PLoS Med; 2018 May; 15(5):e1002565. PubMed ID: 29727458 [TBL] [Abstract][Full Text] [Related]
6. Trends in and correlates of CD4+ cell count at antiretroviral therapy initiation after changes in national ART guidelines in Rwanda. Mutimura E; Addison D; Anastos K; Hoover D; Dusingize JC; Karenzie B; Izimukwiye I; Mutesa L; Nsanzimana S; Nash D; AIDS; 2015 Jan; 29(1):67-76. PubMed ID: 25562492 [TBL] [Abstract][Full Text] [Related]
7. Time-varying age- and CD4-stratified rates of mortality and WHO stage 3 and stage 4 events in children, adolescents and youth 0 to 24 years living with perinatally acquired HIV, before and after antiretroviral therapy initiation in the paediatric IeDEA Global Cohort Consortium. Desmonde S; Neilan AM; Musick B; Patten G; Chokephaibulkit K; Edmonds A; Duda SN; Malateste K; Wools-Kaloustian K; Ciaranello AL; Davies MA; Leroy V; J Int AIDS Soc; 2020 Oct; 23(10):e25617. PubMed ID: 33034417 [TBL] [Abstract][Full Text] [Related]
8. Do HIV treatment eligibility expansions crowd out the sickest? Evidence from rural South Africa. Kluberg SA; Fox MP; LaValley M; Pillay D; Bärnighausen T; Bor J Trop Med Int Health; 2018 Sep; 23(9):968-979. PubMed ID: 29947442 [TBL] [Abstract][Full Text] [Related]
9. Sex-based differences in antiretroviral therapy initiation, switching and treatment interruptions: global overview from the International Epidemiologic Databases to Evaluate AIDS (IeDEA). Giles ML; Achhra AC; Abraham AG; Haas AD; Gill MJ; Lee MP; Luque M; McGowan C; Cornell M; Braitstein P; de Rekeneire N; Becquet R; Wools-Kaloustian K; Law M J Int AIDS Soc; 2018 Jun; 21(6):e25149. PubMed ID: 29956882 [TBL] [Abstract][Full Text] [Related]
10. Population uptake and effectiveness of test-and-treat antiretroviral therapy guidelines for preventing the global spread of HIV: an ecological cross-national analysis. Mendez-Lopez A; McKee M; Stuckler D; Granich R; Gupta S; Noori T; Semenza JC HIV Med; 2019 Sep; 20(8):501-512. PubMed ID: 31140715 [TBL] [Abstract][Full Text] [Related]
11. Treatment guidelines and early loss from care for people living with HIV in Cape Town, South Africa: A retrospective cohort study. Katz IT; Kaplan R; Fitzmaurice G; Leone D; Bangsberg DR; Bekker LG; Orrell C PLoS Med; 2017 Nov; 14(11):e1002434. PubMed ID: 29136014 [TBL] [Abstract][Full Text] [Related]
12. The clock is ticking: the rate and timeliness of antiretroviral therapy initiation from the time of treatment eligibility in Kenya. Odeny TA; DeCenso B; Dansereau E; Gasasira A; Kisia C; Njuguna P; Haakenstad A; Gakidou E; Duber HC J Int AIDS Soc; 2015; 18(1):20019. PubMed ID: 26507824 [TBL] [Abstract][Full Text] [Related]
13. Timing and Predictors of Initiation on Antiretroviral Therapy Among Newly-Diagnosed HIV-Infected Persons in South Africa. Larsen A; Cheyip M; Tesfay A; Vranken P; Fomundam H; Wutoh A; Aynalem G AIDS Behav; 2019 Feb; 23(2):375-385. PubMed ID: 30008050 [TBL] [Abstract][Full Text] [Related]
14. Twelve-year mortality in adults initiating antiretroviral therapy in South Africa. Cornell M; Johnson LF; Wood R; Tanser F; Fox MP; Prozesky H; Schomaker M; Egger M; Davies MA; Boulle A; J Int AIDS Soc; 2017 Sep; 20(1):21902. PubMed ID: 28953328 [TBL] [Abstract][Full Text] [Related]
15. Treatment eligibility and retention in clinical HIV care: A regression discontinuity study in South Africa. Bor J; Fox MP; Rosen S; Venkataramani A; Tanser F; Pillay D; Bärnighausen T PLoS Med; 2017 Nov; 14(11):e1002463. PubMed ID: 29182641 [TBL] [Abstract][Full Text] [Related]
16. Immediate and long-term outcomes after treat-all among people living with HIV in China: an interrupted time series analysis. Wu X; Wu G; Ma P; Wang R; Li L; Sun Y; Xu J; Li Y; Zhang T; Li Q; Yang Y; Wang L; Xin X; Qiao Y; Fang B; Lu Z; Zhou X; Chen Y; Liu Q; Fu G; Wei H; Huang X; Su B; Wang H; Zou H Infect Dis Poverty; 2023 Aug; 12(1):73. PubMed ID: 37580822 [TBL] [Abstract][Full Text] [Related]
17. Trends in demographic and clinical characteristics and initiation of antiretroviral therapy among adult patients enrolling in HIV care in the Central Africa International epidemiology Database to Evaluate AIDS (CA-IeDEA) 2004 to 2018. Adedimeji AA; Hoover DR; Shi Q; Kim HY; Brazier E; Ross J; Murenzi G; Twizere C; Lelo P; Nsonde D; Ajeh R; Dzudie A; Nash D; Yotebieng M; Anastos K; J Int AIDS Soc; 2021 Jun; 24(6):e25672. PubMed ID: 34152663 [TBL] [Abstract][Full Text] [Related]
18. Time to eligibility for antiretroviral therapy in adults with CD4 cell count > 500 cells/μL in rural KwaZulu-Natal, South Africa. McGrath N; Lessells RJ; Newell ML HIV Med; 2015 Sep; 16(8):512-8. PubMed ID: 25959724 [TBL] [Abstract][Full Text] [Related]
19. High rates of loss to follow-up during the first year of pre-antiretroviral therapy for HIV patients at sites providing pre-ART care in Nigeria, 2004-2012. Agolory SG; Auld AF; Odafe S; Shiraishi RW; Dokubo EK; Swaminathan M; Dalhatu I; Onotu D; Abiri O; Debem H; Bashorun A; Ellerbrock TV PLoS One; 2017; 12(9):e0183823. PubMed ID: 28863160 [TBL] [Abstract][Full Text] [Related]
20. Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation. Panayidou K; Davies MA; Anderegg N; Egger M; J Int AIDS Soc; 2018 Nov; 21(11):e25200. PubMed ID: 30614622 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]